艾布罗西坦在高血压管理中:临床疗效,安全性和未来前景
Rumaisa Riaz1, Usaid Ahmed1, Unaiza Naqi1
1Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan.
Annals of medicine and surgery (2012)
|April 11, 2025
概括
在抗性高血压病例中,阿普罗西坦有效降低血压. 这种双重内甲素受体抗剂提供了一个新的治疗选择,但需要仔细监测潜在的副作用,如肝脏毒性.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压 (HTN) 影响全球31.1%,在低至低收入国家有显著影响.
- 脏对于长期的血压调节至关重要;Endothelin-1 (ET-1) 通过血管收缩和血管改造加剧HTN.
- 未经治疗的HTN会导致严重的并发症,如心力衰竭,中风和功能衰竭.
研究的目的:
- 评估Aprocitentan,一种新型的双内甲素受体抗剂,用于治疗抗性高血压.
- 评估阿普罗西坦在控制失控血压时的疗效和安全性.
主要方法:
- 进行了临床试验,包括第三阶段的PRECISION研究.
- 这项研究涉及接受Aprocitentan的耐药高血压患者.
- 收集和分析了有效性和安全性数据,包括不良事件.
主要成果:
- 阿普罗西坦在耐性HTN患者的血压降低方面表现出有效性.
- 第三阶段的PRECISION研究证实了其对长期血压控制的有效性.
- 潜在的安全问题包括肝毒性,液体保留和胚胎胎毒性.
结论:
- 阿普罗西坦在高血压管理方面取得了重大进展.
- 它为患有不受控制的HTN的患者提供了一个新的治疗选择.
- 警监测对于减轻风险和确保最佳结果至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
100
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
100
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
120
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
120
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
Antihypertensive Drugs: Direct Renin Inhibitors
454
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
454
Antihypertensive Drugs: Angiotensin II Receptor Blockers
548
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
548
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
404
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
404


